10-K: Werewolf Therapeutics Faces Going Concern Doubt Amid Restructuring

Werewolf Therapeutics, Inc. announced a significant restructuring, including a 64% workforce reduction, and is exploring strategic alternatives to address substantial doubt about its ability to continue as a going concern.

Summary

• Reported a net loss of $60.8 million for the fiscal year ended December 31, 2025, an improvement from $70.5 million in 2024.
• Cash and cash equivalents stood at $57.1 million as of December 31, 2025, with an accumulated deficit of $475.4 million.
• Cash used in operating activities increased to $60.3 million in 2025 from $56.2 million in 2024.
• Revenue for 2025 was $0, down from $1.9 million in 2024, following the transfer of material performance obligations under the Jazz collaboration agreement.
• Research and development expenses decreased by $11.6 million to $44.8 million in 2025, primarily due to reduced manufacturing costs for WTX-330, WTX-124, WTX-712, and JZP898, partially offset by increased clinical trial costs for WTX-124 and WTX-330.
• General and administrative expenses decreased by $3.2 million to $15.8 million in 2025, mainly due to lower personnel costs and professional service fees.
• A restructuring plan was adopted in February 2026, involving a 64% reduction in workforce, expected to incur a one-time charge of approximately $4.1 million in Q1 2026 for employee separation benefits.
• The company is exploring a full range of strategic alternatives, including a sale, business combination, asset sale, or licensing arrangements, with Piper Sandler & Co. as exclusive financial advisor.
• WTX-124 (IL-2 INDUKINE molecule) Phase 1/1b clinical trial is expected to complete in Q2 2026, with updated interim data (Oct 2025) showing a 21% objective response rate (ORR) as monotherapy in heavily pretreated melanoma patients, and 30% ORR in non-primary resistant patients, with no evidence of vascular leak syndrome.
• The FDA accepted 18 mg as the recommended dose for WTX-124 and provided initial guidance for a monotherapy registration path in post-ICI advanced or metastatic relapsed/refractory melanoma.
• WTX-330 (IL-12 INDUKINE molecule) Phase 1 clinical trial completed in Q1 2025, and a Phase 1b/2 trial was initiated in Q1 2025. Interim data (Oct 2025) showed favorable tolerability and one confirmed partial response (45% tumor reduction) in metastatic gall bladder cancer.
• The company received a Nasdaq deficiency letter on February 4, 2026, for failing to meet the minimum bid price requirement of $1.00 per share, with 180 days to regain compliance by August 3, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with a highly negative sentiment due to the explicit 'going concern' warning, a drastic 64% workforce reduction, zero revenue in 2025, and a Nasdaq delisting notice, all indicating severe financial distress and operational uncertainty.

Positives

• Net loss decreased to $60.8 million in 2025 from $70.5 million in 2024.
• WTX-124 showed a 21% objective response rate as monotherapy in heavily pretreated melanoma patients, consistent with historic high-dose IL-2 activity, and 30% in patients not primary resistant to immunotherapy.
• WTX-124 demonstrated no evidence of vascular leak syndrome or recurrence of prior immune-related adverse events, indicating an improved safety profile compared to traditional IL-2 therapies.
• The FDA accepted 18 mg as the recommended dose for WTX-124 and provided initial guidance for a monotherapy registration path in post-ICI advanced or metastatic relapsed/refractory melanoma, potentially expediting development.
• WTX-330 showed favorable tolerability and antitumor activity, with one confirmed partial response (45% tumor reduction) in metastatic gall bladder cancer, and an optimized manufacturing process improved its safety profile and therapeutic index.
• Preclinical data for WTX-712, WTX-518, and WTX-921 demonstrated promising results, including tumor-selective activation and robust immune responses, indicating platform potential.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from March 27, 2026.
• Cash and cash equivalents of $57.1 million as of December 31, 2025, are expected to fund operations only into Q4 2026, requiring additional funding.
• No revenue was recognized in 2025, a decrease from $1.9 million in 2024, indicating a lack of product sales or significant collaboration income.
• A restructuring plan in February 2026 included a 64% workforce reduction, leading to a one-time charge of approximately $4.1 million and potential adverse effects on employee morale and reputation.
• The company received a Nasdaq deficiency letter on February 4, 2026, for failing to meet the minimum bid price requirement, risking delisting if compliance is not regained by August 3, 2026.
• The success of the strategic review process is uncertain, with no assurance of any agreement or transaction that will enhance stockholder value or mitigate going concern issues.
• The company has a limited operating history, no products approved for commercial sale, and expects to incur significant losses for the foreseeable future.

Risks

• Substantial doubt exists about the ability to continue as a going concern for at least twelve months from the date the consolidated financial statements are issued.
• The company will need additional funding to finance operations and complete development and commercialization of product candidates, with no assurance of availability on acceptable terms.
• The strategic review process may not result in any agreement or transaction that enhances stockholder value or any agreement at all, potentially leading to a decline in stock price.
• A limited operating history, significant operating losses since inception, and no product revenue to date, with expectations of continued losses for the foreseeable future.
• Early stage of development for product candidates, requiring successful completion of extensive preclinical and clinical development before regulatory approval can be sought.
• The PREDATOR platform approach is unproven, and there is no certainty of developing products of commercial value.
• Manufacturing INDUKINE and INDUCER molecules is complex and subject to risks, including unintended proteolysis and difficulties in scaling production to commercial levels.
• Clinical trials are expensive, time-consuming, difficult to design, and involve uncertain outcomes, with results from earlier stages not necessarily predictive of future success.
• Potential for substantial delays, termination, or suspension of clinical trials due to various factors, including patient enrollment difficulties, unexpected side effects, or regulatory changes.
• Development of product candidates in combination with third-party drugs carries risks related to control over safety, supply, regulatory status, and approval of such drugs.
• Substantial competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, which may develop or commercialize products more successfully.
• Reliance on third parties to conduct preclinical studies, clinical trials, and manufacturing, which may not successfully carry out duties or meet deadlines.
• Inability to obtain and maintain patent protection for product candidates or the PREDATOR platform, or if the scope of protection is not broad enough, competitors could develop similar products.
• Exposure to costly and damaging product liability claims during clinical testing or after commercial sale, with insurance potentially inadequate to cover all damages.
• Failure to comply with Nasdaq listing requirements, specifically the minimum bid price, could lead to delisting and negatively impact stock price and access to capital markets.
• Volatility in the common stock price due to various factors, including clinical trial results, regulatory decisions, competition, and general economic conditions.
• Potential for cyberattacks or deficiencies in cybersecurity to result in information theft, data corruption, operational disruption, or financial loss.
• Changes in tax laws or their interpretation, such as the TCJA and IRA, could adversely affect the business and financial condition, including limitations on net operating loss carryforwards.
• Risks associated with marketing product candidates internationally, including differing regulatory requirements, economic instability, and compliance with foreign laws.

Future Outlook

The company is actively exploring a full range of strategic alternatives to advance its platform and drug development pipeline and maximize stockholder value, including potential sale, merger, asset sale, or licensing arrangements. Future development of product candidates, including WTX-124 and WTX-330, is dependent on the outcome of this strategic review and securing additional funding. The company expects overall costs to decrease in the near term due to the recent workforce reduction and other cost-cutting initiatives, but research and development and general and administrative expenses would increase if clinical trials or preclinical development resume.

Management Comments

• Management believes there is substantial doubt about the company's ability to continue as a going concern for at least twelve months from the date these consolidated financial statements are issued.
• The company is currently evaluating strategies to raise additional capital, but there can be no assurances of success in mitigating the going concern conditions.
• The board of directors approved a 64% workforce reduction to better align resources with the pursuit of strategic alternatives.
• Management expects to incur a one-time charge of approximately $4.1 million in Q1 2026 related to employee separation benefits from the restructuring plan.
• The company is currently seeking a strategic partnership for the further development of WTX-124 and WTX-330.

Industry Context

StockSavvy.ai notes that Werewolf Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, particularly in immuno-oncology. The company's PREDATOR platform aims to address limitations of conventional immune therapies by selectively activating molecules in the tumor microenvironment, a differentiated approach in a crowded field. The focus on IL-2 and IL-12 INDUKINE molecules places them in direct competition with numerous established and emerging players developing similar cytokine-based immunotherapies, as well as other modalities like monoclonal antibodies and cell therapies. The ongoing strategic review and significant workforce reduction reflect broader industry pressures on early-stage biotechs to demonstrate clear paths to commercialization and financial sustainability, especially in a challenging funding environment.

Comparison to Industry Standards

• WTX-124's 21% objective response rate as monotherapy in heavily pretreated melanoma patients is consistent with historic high-dose IL-2 activity (e.g., Proleukin/aldesleukin), suggesting competitive efficacy without the severe toxicities like vascular leak syndrome.
• The 30% objective response rate for WTX-124 in melanoma patients not primary resistant to immunotherapy indicates a potentially strong performance in a specific patient subset, which could differentiate it from other IL-2 therapies in development from companies like Anaveon AG, Ascendis Pharma A/S, and Xilio Therapeutics, Inc.
• WTX-330's confirmed partial response in metastatic gall bladder cancer with a 45% reduction in tumor target lesions is a notable early efficacy signal, especially given the challenging nature of this tumor type and prior failures of standard of care. This compares favorably to the limited clinical activity and significant toxicity observed in early trials of systemically administered recombinant human IL-12 by third parties.
• The optimized manufacturing process for WTX-330, leading to a 17-fold higher Cmax than published rhIL-12 and very low free IL-12 levels, suggests a superior therapeutic index compared to historical IL-12 approaches and potentially other IL-12 programs from competitors like Sanofi S.A. (Amunix) and DragonFly Therapeutics, Inc.

Management Changes

Corporate Governance

Related Party Transactions

• Royalty Transfer Agreement: Obligation to pay a 0.5% royalty on net sales of products to MPM Oncology Impact Fund Charitable Foundation, Inc. and UBS Optimus Foundation. These foundations are affiliated with MPM Capital and UBS Oncology Impact Fund L.P., respectively, where directors Luke Evnin and Ansbert Gadicke hold managing roles.
• Sublease Agreement: Entered into a sublease agreement with Crossbow Therapeutics, Inc. (where director Briggs Morrison serves as CEO and MPM Capital affiliates are beneficial owners) for office and laboratory space. The company received approximately $0.4 million in cash payments under this sublease in 2024.

Stakeholder Impact

• Shareholders: Face significant risk of investment loss due to 'going concern' doubt, potential delisting from Nasdaq, and dilution from future capital raises. The strategic review process introduces uncertainty regarding future value.
• Employees: Directly impacted by the 64% workforce reduction, leading to job losses and potential adverse effects on morale for remaining staff. The restructuring plan includes severance benefits for affected employees.
• Patients: Development of promising product candidates (WTX-124, WTX-330) may be delayed or halted if additional funding or strategic partnerships are not secured, potentially limiting access to novel cancer therapies.
• Creditors: The K2HV Loan Agreement includes a first priority security interest on substantially all assets (excluding intellectual property), and an event of default could lead to acceleration of obligations.
• Partners (e.g., Jazz Pharmaceuticals): The company's financial instability and strategic review could impact existing collaborations, although the material performance obligations for JZP898 have been transferred to Jazz.

Next Steps

• Continue the strategic review process to explore options such as a sale, business combination, asset sale, or licensing arrangements.
• Seek additional funding through public or private equity offerings, debt financings, collaborations, or licensing arrangements.
• Complete the Phase 1/1b clinical trial of WTX-124, expected in Q2 2026.
• Complete Part A of the Phase 1b/2 clinical trial of WTX-330, expected in Q2 2026.
• Initiate further development of WTX-124, potentially including a registration-enabling trial, contingent on additional funding and strategic partnerships.
• Further develop WTX-330, potentially including sequential administration with WTX-124, contingent on additional funding and strategic partnerships.
• Regain compliance with Nasdaq's minimum bid price requirement by August 3, 2026, to avoid delisting.
• Manage the one-time charge of approximately $4.1 million in Q1 2026 related to employee separation benefits from the restructuring plan.
• Continue to manage and protect intellectual property, including prosecuting patent applications and enforcing existing patents.

Key Dates

Recommendation

The filing presents a dire financial situation, explicitly stating 'substantial doubt about our ability to continue as a going concern.' This is compounded by a massive 64% workforce reduction, zero revenue in the last fiscal year, and a Nasdaq delisting notice. While clinical data for WTX-124 and WTX-330 show promise, the company's ability to fund further development and commercialization is severely compromised. The ongoing strategic review offers no guarantee of a favorable outcome. These factors collectively indicate extreme financial risk and a high probability of significant shareholder value erosion, warranting a strong sell recommendation.

Keywords

Biopharmaceutical, Oncology, Immunotherapy, PREDATOR platform, IND-enabling studies, Clinical trials, WTX-124, WTX-330, IL-2 INDUKINE, IL-12 INDUKINE, Strategic alternatives, Workforce reduction, Going concern, Nasdaq delisting risk, Capital raise, Patent protection, Regulatory approval